HIGH DOSE CYCLOPHOSPHAMIDE, TACROLIMUS, AND MYCOPHENOLATE MOFETIL IN PREVENTING GRAFT VERSUS HOST DISEASE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES UNDERGOING MYELOABLATIVE OR REDUCED INTENSITY DONOR STEM CELL TRANSPLANT: